CN117396473A - 血浆激肽释放酶的咪唑并吡啶基抑制剂 - Google Patents

血浆激肽释放酶的咪唑并吡啶基抑制剂 Download PDF

Info

Publication number
CN117396473A
CN117396473A CN202280033913.6A CN202280033913A CN117396473A CN 117396473 A CN117396473 A CN 117396473A CN 202280033913 A CN202280033913 A CN 202280033913A CN 117396473 A CN117396473 A CN 117396473A
Authority
CN
China
Prior art keywords
compound
pyridin
mmol
cyclopropylimidazo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280033913.6A
Other languages
English (en)
Chinese (zh)
Inventor
N·帕帕约安努
J·M·特拉文斯
S·J·芬克
J·M·埃拉德
A·雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN117396473A publication Critical patent/CN117396473A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280033913.6A 2021-03-17 2022-03-16 血浆激肽释放酶的咪唑并吡啶基抑制剂 Pending CN117396473A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162494P 2021-03-17 2021-03-17
US63/162,494 2021-03-17
PCT/US2022/020474 WO2022197755A1 (en) 2021-03-17 2022-03-16 Imidazopyridinyl inhibitors of plasma kallikrein

Publications (1)

Publication Number Publication Date
CN117396473A true CN117396473A (zh) 2024-01-12

Family

ID=81325446

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280033913.6A Pending CN117396473A (zh) 2021-03-17 2022-03-16 血浆激肽释放酶的咪唑并吡啶基抑制剂

Country Status (4)

Country Link
EP (1) EP4308227A1 (https=)
JP (1) JP2024510502A (https=)
CN (1) CN117396473A (https=)
WO (1) WO2022197755A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4031547B1 (en) 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027107A2 (en) * 1999-10-12 2001-04-19 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
WO2010132598A1 (en) * 2009-05-13 2010-11-18 Amgen Inc. Heteroaryl compounds as pikk inhibitors
WO2012051036A1 (en) * 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
WO2015099196A1 (en) * 2013-12-26 2015-07-02 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
CN117355521A (zh) * 2021-03-17 2024-01-05 武田药品工业株式会社 血浆激肽释放酶的杂芳基抑制剂
CN117396474A (zh) * 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20050192314A1 (en) * 2003-11-13 2005-09-01 Ambit Biosciences Corporation Urea derivatives as C-kit modulators
JP6665154B2 (ja) * 2014-07-17 2020-03-13 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 置換尿素誘導体及びその薬学的使用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027107A2 (en) * 1999-10-12 2001-04-19 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
WO2010132598A1 (en) * 2009-05-13 2010-11-18 Amgen Inc. Heteroaryl compounds as pikk inhibitors
WO2012051036A1 (en) * 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
WO2015099196A1 (en) * 2013-12-26 2015-07-02 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
CN117355521A (zh) * 2021-03-17 2024-01-05 武田药品工业株式会社 血浆激肽释放酶的杂芳基抑制剂
CN117396474A (zh) * 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶抑制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLIMBUS, OHIO, US: "REGISTRY[online]", 《REGISTRY》, 17 August 2022 (2022-08-17), pages 1316344 - 05 *
MARTIN ROATSCH ET AL.: "Substituted 2-(2-Aminopyrimidin-4-Yl)Pyridine-4- Carboxylates as Potent Inhibitors of Jumonjic Domain-Containing Histone Demethylases", 《FUTURE MEDICINAL CHEMISTRY》, 14 March 2016 (2016-03-14), pages 1553 - 1571 *
尤启东等: "《药物化学》", 31 January 2004, 化学工业出版社, pages: 32 - 34 *

Also Published As

Publication number Publication date
WO2022197755A1 (en) 2022-09-22
EP4308227A1 (en) 2024-01-24
JP2024510502A (ja) 2024-03-07

Similar Documents

Publication Publication Date Title
AU2020343671B2 (en) RIP1 inhibitory compounds and methods for making and using the same
CN114728962B (zh) 血浆激肽释放酶抑制剂及其用途
KR102534962B1 (ko) 8,9-디하이드로이미다졸[1,2-a]피리미도[5,4-e]피리미딘-5(6H)-케톤계 화합물
EP3774797B1 (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
RU2674701C2 (ru) Аминопиридазиноновые соединения в качестве ингибиторов протеинкиназы
EP3500569B1 (en) 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof
EP4695226A1 (en) Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
CA3022044A1 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
JP2010522186A (ja) 化合物
CN118215664B (zh) 取代的三唑并杂芳基化合物作为usp1抑制剂及其应用
CN117396473A (zh) 血浆激肽释放酶的咪唑并吡啶基抑制剂
WO2017071516A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
CN114667289B (zh) 杂芳基血浆激肽释放酶抑制剂
TW202122382A (zh) 乙內醯脲衍生物
CN117355523A (zh) 血浆激肽释放酶的多环抑制剂
WO2019011228A1 (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
JP7688242B1 (ja) ３－フェニルプロピルアミン誘導体
JP2023535932A (ja) 三環式のヘテロ環
CN117396469A (zh) 血浆激肽释放酶的抑制剂
US20180118718A1 (en) Substituted Quinoxaline Derivatives
JP2022515309A (ja) 置換アリール化合物、その製造方法及び用途
WO2024145505A1 (en) Pyrimidine carboxamide compounds
JP2024512753A (ja) 新規なジアルコキシナフト［２，３－ｃ］フラン－１（３Ｈ）－オン誘導体およびこれを含む呼吸器疾患またはＳＡＲＳ－ＣｏＶ－２感染症の予防または治療用の薬学的組成物
US20240199612A1 (en) Imidazopyridinyl inhibitors of plasma kallikrein
TWI894448B (zh) Ctla-4小分子降解劑及其應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination